EssilorLuxottica has acquired Ikerian AG, enhancing its med-tech portfolio with advanced AI-driven eyecare solutions to improve patient outcomes globally.
Target Information: Ikerian AG
EssilorLuxottica has announced the acquisition of Ikerian AG, a health technology company operating under the RetinAI brand. Ikerian is renowned for its expertise in artificial intelligence and data management within the eyecare sector. This strategic move aligns with EssilorLuxottica's commitment to advancing its med-tech portfolio by incorporating cutting-edge software that utilizes machine learning and computer vision.
The flagship platform, RetinAI Discovery, developed by Ikerian, is FDA cleared (510(k)) and CE-marked, providing formidable tools for collecting, processing, and analyzing extensive retinal images and biomarker datasets. This technology supports the diagnosis and monitoring of various eye diseases, including age-related macular degeneration, glaucoma, and diabetic retinopathy, enabling healthcare professionals to make more accurate and timely decisions in patient care.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the Eyecare Sector
The eyecare industry continues to evolve, driven by advancements in technology and the growing prevalence of eye-related disorders globally. In recent years, the integration of artificial intelligence in healthcare has revolutionized diagnostic
Similar Deals
Penta Hospitals → Group Mediterra, a.s.
2025
EssilorLuxottica
invested in
Ikerian AG
in 2023
in a Merger deal